Albireo Pharma

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

‒ Achieved primary endpoint ‒  ‒ Unremarkable results in key NASH measures ‒  ‒ Company discontinuing further development ‒

Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NASH

Albireo Pharma, Inc.'s (ALBO) CEO Ron Cooper on Q2 2020 Results - Earnings Call Transcript

— Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials ——  Enrolled first biliary atresia patients in second odevixibat pivotal study ——  Completed two financing transactions to secure cash into beginning of 2022 ——  Management to host conference call and webcast today at 10:00 a.m. ET —

Albireo Reports Q2 2020 Financial Results and Provides Business Update

BOSTON, July  30, 2020  (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat presentation at the virtual William Blair Biotech Focus Conference 2020 on Thursday, August 6, at 2 p.m. EDT.

Albireo to Present at the William Blair Biotech Focus Conference 2020

—  Conference call and webcast to be held at 10:00 a.m. ET  — 

Albireo to Report Q2 2020 Financial Results on August 6

— Program expands access to odevixibat for patients with progressive familial intrahepatic cholestasis (PFIC), an ultra-rare pediatric cholestatic liver disease — — Program expands access to odevixibat for patients with progressive familial intrahepatic cholestasis (PFIC), an ultra-rare pediatric cholestatic liver disease —

Albireo Launches Expanded Access Program for Odevixibat for Patients in the U.S., Canada, Australia and Europe

—  BOLD is first-ever pivotal trial for biliary atresia  —

Albireo Enrolls First Patient in Phase 3 Clinical Trial of Odevixibat in Biliary Atresia

Investors need to pay close attention to Albireo (ALBO) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Albireo (ALBO) Stock?

Albireo Pharma (ALBO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Albireo Pharma (ALBO) Stock Might be a Great Pick

BOSTON, June  10, 2020  (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that it will host a Key Opinion Leader (KOL) call on clinical outcome assessments (COAs) on Tuesday, June 16th at 8:00 am Eastern Time.

Albireo to Host Key Opinion Leader Call on Clinical Outcome Assessments

— Restructured HealthCare Royalty Partners elobixibat royalty monetization agreement nets additional $15M in non-dilutive capital — 

Albireo Announces Two Financing Transactions to Extend Cash Runway Into the Beginning of 2022

Albireo Pharma, Inc.'s (ALBO) CEO Ron Cooper on Q1 2020 Results - Earnings Call Transcript

Shares of Albireo Pharma (NASDAQ:ALBO) were flat in pre-market trading after the company reported Q1 results.

Recap: Albireo Pharma Q1 Earnings

BOSTON, April  07, 2020  (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Simon Harford, Chief Financial Officer, will present via webcast at the 19th Annual Needham Healthcare Conference on Tuesday, April 14, at 2:10 p.m. EDT.

Albireo to Present at 19th Annual Needham Healthcare Conference

Albireo Pharma like so many small biotech names has been hit hard during the recent COVID-19 market meltdown.

Assessing Albireo Pharma

On  track to report topline  data mid-2020

Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLD

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q4 2019 Results - Earnings Call Transcript

Albireo Pharma: View Ahead Of Phase 3 Data In Progressive Familial Intrahepatic Cholestasis In Mid-2020

BOSTON, Feb.  03, 2020  (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the completion of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per share. In addition, the underwriters have exercised in full an option to purchase an additional 285,750 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering were sold by Albireo, with gross proceeds to Albireo of approximately $46.0 million and net proceeds of approximately $42.9 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Albireo Announces Closing of $46 Million Public Offering Including Exercise in Full of Underwriters’ Option to Purchase Additional Shares

BOSTON, Jan.  29, 2020  (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per share. Albireo’s gross proceeds from this offering are expected to be approximately $40 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Albireo has granted the underwriters a 30-day option to purchase up to an additional 285,750 shares of common stock on the same terms and conditions. All of the shares in the offering are being sold by Albireo. The offering is expected to close on or about February 3, 2020, subject to customary closing conditions.

Albireo Prices $40 Million Public Offering of Common Stock

BOSTON, Jan.  29, 2020  (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced a proposed underwritten public offering of its common stock. In connection with the offering, Albireo intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the offering. All of the shares in the offering will be sold by Albireo. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Albireo Announces Proposed Public Offering of Common Stock

—  Reiterates Top Line Data on Phase 3 in PFIC Expected Mid-2020  — — To Initiate Pivotal Trials in Biliary Atresia and Alagille Syndrome in 2020  —

Albireo Achieves Significant Milestones for Odevixibat Across Multiple Diseases

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q3 2019 Results - Earnings Call Transcript

Senior leader with demonstrated experience building high-performing businesses and teams Senior leader with demonstrated experience building high-performing businesses and teams

Albireo Appoints Michelle Graham as Chief Human Resources Officer

Presentations highlight data on odevixibat’s minimal systemic exposure and Albireo’s proprietary pruritus assessment tools Presentations highlight data on odevixibat’s minimal systemic exposure and Albireo’s proprietary pruritus assessment tools

News for Albireo Pharma Stock (ALBO)